CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 63 enrolled
Drug / intervention
MMT-7003 subcutaneous glucose sensordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00865345
NCT00865345N/ACompleted

An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance

Medtronic MiniMed, Inc.·interventional·Posted Mar 19, 2009·Updated Nov 6, 2012

In Brief

A clinical study evaluating MMT-7003 subcutaneous glucose sensor for Diabetes. Completed, enrolled 63 participants across 3 sites.

Detailed Summary

The purpose of this study is to assess the performance of the subcutaneous glucose sensor over an extended sensor life. The sensor is currently approved for 3 days of use and this study will examine sensor safety and accuracy when used for six days. This study will also test sensor safety and accuracy when inserted in an alternate body location (buttock area in addition to abdomen area). The study hypothesis is that the sensor performance will not greatly diminish when used for six days, or in an alternate insertion area.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 19, 2009
Enrollment StartMar 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.3 years ago

Interventions

MMT-7003 subcutaneous glucose sensordevice

All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.